Measuring the effect of elexacaftor/tezacaftor/ivacaftor combination therapy on the respiratory pump in people with CF using dynamic chest radiography.

[1]  M. Drumm,et al.  Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration , 2021, European Respiratory Journal.

[2]  H. Tiddens,et al.  The evolving role of radiological imaging in cystic fibrosis , 2021, Current opinion in pulmonary medicine.

[3]  T. Hajiro,et al.  Prediction of forced vital capacity with dynamic chest radiography in interstitial lung disease. , 2021, European Journal of Radiology.

[4]  P. Burgel,et al.  Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. , 2021, Respiratory medicine and research.

[5]  M. Walshaw,et al.  P102 Utility of Dynamic Chest Radiography (DCR) for calculating lung volume subdivisions in adult people with cystic fibrosis , 2021 .

[6]  M. Jinzaki,et al.  Projected lung areas using dynamic X-ray (DXR) , 2020, European Journal of Radiology Open.

[7]  J. Woods,et al.  Novel imaging techniques for cystic fibrosis lung disease , 2020, Pediatric pulmonology.

[8]  C. Owen,et al.  Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[9]  Z. Kmietowicz.  Covid-19: Highest risk patients are asked to stay at home for 12 weeks , 2020, BMJ.

[10]  R. Bedi,et al.  Utility and validity of dynamic chest radiography in cystic fibrosis (dynamic CF): an observational, non-controlled, non-randomised, single-centre, prospective study , 2020, BMJ Open Respiratory Research.

[11]  C. Teneback,et al.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.

[12]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[13]  M. Jinzaki,et al.  Time-resolved quantitative evaluation of diaphragmatic motion during forced breathing in a health screening cohort in a standing position: Dynamic chest phrenicography. , 2019, European journal of radiology.

[14]  M. Jinzaki,et al.  Decreased and slower diaphragmatic motion during forced breathing in severe COPD patients: Time-resolved quantitative analysis using dynamic chest radiography with a flat panel detector system. , 2019, European journal of radiology.

[15]  E. Ingenito,et al.  Tezacaftor–Ivacaftor in Residual‐Function Heterozygotes with Cystic Fibrosis , 2017, The New England journal of medicine.

[16]  E. Ingenito,et al.  Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del , 2017, The New England journal of medicine.

[17]  S. Stanojevic,et al.  Physiologic endpoints for clinical studies for cystic fibrosis. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[18]  D. Radzioch,et al.  Lack of CFTR in Skeletal Muscle Predisposes to Muscle Wasting and Diaphragm Muscle Pump Failure in Cystic Fibrosis Mice , 2009, PLoS genetics.

[19]  A. Ionescu,et al.  The influence of body composition on respiratory muscle, lung function and diaphragm thickness in adults with cystic fibrosis. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[20]  A. Coates,et al.  Lung recoil and the determination of airflow limitation in cystic fibrosis and asthma , 1993, Pediatric pulmonology.